Literature DB >> 17496941

Sigmoid colon is an unexpected organ at risk in brachytherapy for cervix cancer.

Hoda Al-Booz1, Ion Boiangiu, Helen Appleby, Chris French, Helen Coomber, Pauline Humphery, Paul Cornes.   

Abstract

PURPOSE: To identify organs at risk (OAR) and analyze the dose volume histograms (DVHs) for intracavitary brachytherapy in cancer of the cervix. Late toxicities are our concern in treatment of cancer cervix especially as it is presenting in younger age population.
MATERIAL AND METHODS: Patients with cancer of the cervix were treated using CT and MRI compatible, high dose rate, (HDR) applicators. CT images were acquired with the intra-uterine tube and colpostats in place and subsequently imported into Varian Brachyvision planning software. We identified the gross tumour volume (GTV) and organs at risk (OARs) and analyzed the dose distribution using dose volume histograms (DVHs). Doses were calculated according to ICRU 38. Critical tissue DVHs were analysed following the American Brachytherapy Society rules. Dose points are recorded as the dose encompassed by the greatest contiguous 1 cm3, 2 cm3, and 5 cm3 volumes in the plan.
RESULTS: We found the sigmoid colon to be a relatively immobile structure that repeatedly received doses in excess of 70% of the intended point A dose. The only solution in order to bring sigmoid DVHs within 5% toxicity limits was to reduce the dose to point A. Planning images and DVHs for the OARs are shown as an example of our work.
CONCLUSION: The recto-sigmoid colon is identified as an unexpected OAR in a majority of cervix brachytherapy plans. A new consensus on the DVH limit of this structure will be needed in the era of CT planned brachytherapy, if arbitrary dose reductions to point A are to be the solution to the problem of sigmoid DVHs that exceed conventional tolerance limits.

Entities:  

Mesh:

Year:  2006        PMID: 17496941

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  7 in total

1.  Facilitated early ileostomy closure after rectal cancer surgery: a case-matched study.

Authors:  S Memon; A G Heriot; C E Atkin; A C Lynch
Journal:  Tech Coloproctol       Date:  2012-05-23       Impact factor: 3.781

2.  Sigmoid dose using 3D imaging in cervical-cancer brachytherapy.

Authors:  Caroline L Holloway; Marie-Lynn Racine; Robert A Cormack; Desmond A O'Farrell; Akila N Viswanathan
Journal:  Radiother Oncol       Date:  2009-08-06       Impact factor: 6.280

Review 3.  Image-based brachytherapy for cervical cancer.

Authors:  John A Vargo; Sushil Beriwal
Journal:  World J Clin Oncol       Date:  2014-12-10

4.  Bladder (ICRU) dose point does not predict urinary acute toxicity in adjuvant isolated vaginal vault high-dose-rate brachytherapy for intermediate-risk endometrial cancer.

Authors:  Lucas Gomes Sapienza; Antonio Aiza; Maria José Leite Gomes; Michael Jenwei Chen; Antonio Cassio de Assis Pellizzon; David B Mansur; Glauco Baiocchi
Journal:  J Contemp Brachytherapy       Date:  2015-10-13

5.  A comprehensive evaluation of adaptive daily planning for cervical cancer HDR brachytherapy.

Authors:  Rebecca Meerschaert; Adrian Nalichowski; Jay Burmeister; Arun Paul; Steven Miller; Zhenghui Hu; Ling Zhuang
Journal:  J Appl Clin Med Phys       Date:  2016-11-08       Impact factor: 2.102

6.  Evaluation of dosimetric impact of inter-application and intra-application variations in fractionated high-dose-rate intra-cavitary brachytherapy of cervical cancer.

Authors:  Tanvir Pasha; Hanan Naniparuthayil Hassan; Nikhila Radhakrishna; Muhammed Shafeeque N; Ajin Shaji Varghese; Lokesh Viswanath; Nithin Bhaskar Valuvil; Sathiyan S; Govardhan H B; Ibrahim Khaleel; Siddanna Rudrappa Palled; Naveen Thimmaiah
Journal:  J Contemp Brachytherapy       Date:  2021-12-30

7.  Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses.

Authors:  Cem Onal; Gungor Arslan; Erkan Topkan; Berrin Pehlivan; Melek Yavuz; Ezgi Oymak; Aydin Yavuz
Journal:  J Exp Clin Cancer Res       Date:  2009-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.